Evidence map›Paper›PMID 36429409›Full record

ArticleInternational journal of environmental research and public health2022

Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan.

Takehiro Ishida, Asuka Suzuki, Yoshinori Nakata

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takehiro IshidaGraduate School of Public Health, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan.ORCID 0000-0003-4955-3055
Asuka SuzukiGraduate School of Public Health, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan.ORCID 0000-0002-5102-696X
Yoshinori NakataGraduate School of Public Health, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan.ORCID 0000-0003-2252-3358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polypharmacy is a serious health issue for older adults worldwide, including in Japan, which has a rapidly aging society. The "Proper Medication Guideline for Older Adults" was published for healthcare providers in May 2018, and polypharmacy reduction incentives were initiated for medical facilities in April 2016 and April 2018. This study identified the long-term reduction in polypharmacy prescriptions focusing on older adults aged 75 years and above from April 2015 to March 2019. The national health insurance claims database, which covers most reimbursement claims in Japan, was selected as the primary data source. In this study, polypharmacy was defined as the simultaneous prescription of seven or more medications or multi-psychotropic medications. The primary outcome was the polypharmacy reduction ratio, which indicates the decrease in polypharmacy proportion based on the number of medications on an outpatient prescription. A total polypharmacy reduction of 19.3% for the "75-89 years" subgroup and 16.5% for the "90 years and above" subgroup was observed over four years. Based on prefecture analysis, the mean values of polypharmacy proportion showed a statistically significant reduction over four years. This study showed a successful nationwide reduction in polypharmacy prescriptions after implementing the polypharmacy management guidelines for older adults and incentive-based policies.

Indexed as

PolypharmacyPsychotropic DrugsAgedAgingHumansJapanPolicyPsychotropic Drugsagedappropriate prescribinghealth policypolypharmacyprescription feespublic healthreal-world evidence

Identifiers

PMID36429409
PMCPMC9691254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.